Sporotrichosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Matt Pijoan (talk | contribs) No edit summary |
||
Line 5: | Line 5: | ||
==Treatment== | ==Treatment== | ||
{| class="wikitable" | {|class="wikitable"| style="border: 0px; font-size: 90%; margin: 3px; width: 80%" align=center | ||
!Form | |valign=top| | ||
!Primary Line of Treatment | |+ | ||
!Alternative Treatment | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Form}} | ||
!Remarks/Other | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Primary Line of Treatment}} | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Alternative Treatment}} | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Remarks/Other}} | |||
|- | |- | ||
|Uncomplicated cutaneous | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Uncomplicated cutaneous | ||
| | | | ||
* [[Itraconazole]] 200 mg | * [[Itraconazole]] 200 mg PO qd | ||
| | | | ||
* [[Itraconazole]] 200 mg PO bid, {{Or}} | * [[Itraconazole]] 200 mg PO bid, {{Or}} | ||
* [[Terbinafine]] 500 mg PO bid, {{Or}} | * [[Terbinafine]] 500 mg PO bid, {{Or}} | ||
* [[Potassium iodide|SSKI]] increasing doses, {{Or}} | * [[Potassium iodide|SSKI]] increasing doses, {{Or}} | ||
* [[Fluconazole]] 400-800 | * [[Fluconazole]] 400-800 mg PO qd, {{Or}} | ||
* Local hyperthermia | * Local hyperthermia | ||
|Continue treatment for 2-4 weeks after lesions resolve. | |Continue treatment for 2-4 weeks after lesions resolve. | ||
|- | |- | ||
|Osteoarticular | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Osteoarticular | ||
| | | | ||
* [[Itraconazole]] 200 mg PO bid | * [[Itraconazole]] 200 mg PO bid | ||
| | | | ||
* Limposomal amphotericin B 3-5 mg/kg | * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>''' | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd until symptom resolution | ||
|For a total of 12 months, switch to [[Itraconazole]] after resolution/end of treatment. | |For a total of 12 months, switch to [[Itraconazole]] after resolution/end of treatment. | ||
|- | |- | ||
|Pulmonary | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Pulmonary | ||
| | | | ||
* Limposomal [[amphotericin B]] 3-5 mg/kg | * Limposomal [[amphotericin B]] 3-5 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid | * [[Itraconazole]] 200 mg PO bid | ||
| | | | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid upon symptom resolution | * [[Itraconazole]] 200 mg PO bid upon symptom resolution | ||
|Treat less sever cases with a 12 month regimen of [[Itraconazole]]. | |Treat less sever cases with a 12 month regimen of [[Itraconazole]]. | ||
|- | |- | ||
|Meningeal | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Meningeal | ||
| | | | ||
* Limposomal amphotericin B 3-5 mg/kg | * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid | * [[Itraconazole]] 200 mg PO bid | ||
| | | | ||
* Deoxycholate amphotericin B 0.7-1 mg/kg | * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>''' | ||
* [[Itraconazole]] 200 mg PO bid upon symptom resolution | * [[Itraconazole]] 200 mg PO bid upon symptom resolution | ||
|Precise length of amphotericin B treatment varies. Suppressive treatment with [[Itraconazole]] is necessary. | |Precise length of amphotericin B treatment varies. Suppressive treatment with [[Itraconazole]] is necessary. | ||
|- | |- | ||
|Dissimated | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Dissimated | ||
| | | | ||
* Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>''' | * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>''' | ||
Line 57: | Line 59: | ||
|Continue amphotericin B treatment until patient shows marked improvement for a minimum of 12 months. Suppressive treatment with [[Itraconazole]] is necessary. | |Continue amphotericin B treatment until patient shows marked improvement for a minimum of 12 months. Suppressive treatment with [[Itraconazole]] is necessary. | ||
|- | |- | ||
|Sporotrichosis in pregnant women | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sporotrichosis in pregnant women | ||
| colspan="2" | | | colspan="2" | | ||
* Treat with limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>''' | * Treat with limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>''' | ||
Line 65: | Line 67: | ||
|It is preferable to defer treatment in uncomplicated cases. | |It is preferable to defer treatment in uncomplicated cases. | ||
|- | |- | ||
|Sporotrichosis in Children | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sporotrichosis in Children | ||
| | | | ||
* [[Itraconazole]] 6-10 mg PO qd to a max of 400 mg PO qd for mild cases '''<u>OR</u>''' | * [[Itraconazole]] 6-10 mg PO qd to a max of 400 mg PO qd for mild cases '''<u>OR</u>''' |
Revision as of 17:32, 13 January 2016
Sporotrichosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Sporotrichosis medical therapy On the Web |
American Roentgen Ray Society Images of Sporotrichosis medical therapy |
Risk calculators and risk factors for Sporotrichosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alison Leibowitz [2]
Treatment
Form | Primary Line of Treatment | Alternative Treatment | Remarks/Other |
---|---|---|---|
Uncomplicated cutaneous |
|
|
Continue treatment for 2-4 weeks after lesions resolve. |
Osteoarticular |
|
|
For a total of 12 months, switch to Itraconazole after resolution/end of treatment. |
Pulmonary |
|
|
Treat less sever cases with a 12 month regimen of Itraconazole. |
Meningeal |
|
|
Precise length of amphotericin B treatment varies. Suppressive treatment with Itraconazole is necessary. |
Dissimated |
|
|
Continue amphotericin B treatment until patient shows marked improvement for a minimum of 12 months. Suppressive treatment with Itraconazole is necessary. |
Sporotrichosis in pregnant women |
|
It is preferable to defer treatment in uncomplicated cases. | |
Sporotrichosis in Children |
|
|
References
- ↑ Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America (2007). "Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (10): 1255–65. doi:10.1086/522765. PMID 17968818.